Summary & Overview
CPT 88239: Cell Culture From Solid Tumor for Neoplastic Disorder
CPT code 88239 denotes a laboratory procedure for culturing cells from a solid tumor in the evaluation of a neoplastic disorder. Nationally relevant to pathology and oncology services, this code captures a specialized laboratory process that supports diagnostic characterization, ancillary testing, and potential downstream therapeutic decision-making. The code is used by hospital and independent laboratories that perform cell culture from tumor tissue.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare (UHC), and Medicare. Readers will find a concise explanation of the clinical and laboratory context for the code, typical sites of service, common payer coverage considerations, and the set of common modifiers associated with claims for this procedure. The publication summarizes benchmark information where available, notes policy updates affecting laboratory coding and billing for oncology-related cell culture procedures, and highlights operational considerations for hospital and independent laboratory service lines.
This summary is intended to provide coders, billing managers, and oncology practice administrators with a clear overview of what CPT code 88239 represents, its role in the diagnostic pathway for solid tumors, and the payer landscape relevant to reimbursement and claims processing.
Billing Code Overview
CPT code 88239 describes a laboratory procedure in which a lab analyst cultures cells derived from a solid tumor to grow a cell population for evaluation in the context of a neoplastic disorder. This procedure is a cell culture from a solid tumor used for diagnostic, prognostic, or research-related purposes in oncology.
-
Service type: Laboratory cell culture procedure for neoplastic tissue
-
Typical site of service: Hospital laboratory or independent clinical pathology/laboratory facility
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a newly diagnosed solid neoplasm (e.g., lung, breast, or colorectal carcinoma) undergoes a diagnostic tumor biopsy. The surgical pathology team receives the resection or core biopsy specimen and forwards a portion for specialized laboratory culture to establish a viable cell culture from the solid tumor for downstream testing (cytogenetics, drug sensitivity assays, molecular studies, or creation of patient-derived xenograft material). The clinical workflow: biopsy or surgical specimen collection in an ambulatory surgical center or inpatient operating room → transport to pathology/clinical laboratory with appropriate specimen labeling and requisition → accessioning and grossing by pathology → selection and aseptic processing of viable tumor tissue by the laboratory analyst → placement into culture media and incubation under defined conditions documented in the laboratory information system → monitoring and expansion of tumor cell colonies for subsequent analyses. Typical site of service: hospital pathology laboratory, hospital-based outpatient laboratory, or specialized cancer center laboratory. Typical patient scenario: specimen obtained during biopsy or surgical excision for a solid tumor; physician orders culture for diagnostic cytogenetics, research, or therapeutic planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional interpretation component if split billing applies. |